INO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Inovio Pharmaceuticals Inc (INO) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company is facing significant legal challenges, a history of manufacturing delays, and weak financial performance. Additionally, there are no strong technical or proprietary trading signals to suggest a compelling entry point at this time.
The MACD histogram is positive but contracting, suggesting weakening bullish momentum. RSI is neutral at 39.704, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 1.561), with resistance at 1.654. Overall, the technical indicators do not provide a strong buy signal.
NULL identified. The company has no recent positive news or developments.
Multiple lawsuits and investigations into securities violations, manufacturing delays for INO-3107, and a history of stock price declines following negative news. Additionally, the company has shown no significant insider or hedge fund activity to indicate confidence.
In Q3 2025, revenue remained at 0 with no growth. Net income improved YoY but remains deeply negative at -$45.5M. EPS dropped to -0.87, and gross margin stayed flat at 100%. Overall, the financial performance is weak and does not support a long-term investment case.
No recent analyst rating or price target changes are available. The lack of analyst activity suggests limited confidence or interest in the stock.
